5 Stocks Improving Performance Of The Drugs Industry

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 14,544 as of Monday, April 22, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,423 issues advancing vs. 1,490 declining with 125 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.3%. A company within the industry that fell today was Pfizer ( PFE), up 0.45.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Biogen Idec ( BIIB) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biogen Idec is up $9.93 (4.89) to $213.20 on heavy volume Thus far, 1.7 million shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $204.36-$214.13 after having opened the day at $204.86 as compared to the previous trading day's close of $203.27.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $46.9 billion and is part of the health care sector. The company has a P/E ratio of 34.5, above the S&P 500 P/E ratio of 17.7. Shares are up 35.7% year to date as of the close of trading on Friday.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Biogen Idec Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire